Find, compare & contact
Ferrous tartrate
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ferrous tartrate API 2944-65-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ferrous tartrate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ferrous tartrate
- Synonyms:
- Cas Number:
- 2944-65-2
- DrugBank number:
- DB13639
- Unique Ingredient Identifier:
- ZRW631PTZD
General Description:
Ferrous tartrate is a chemical compound identified by the CAS number 2944-65-2. It is known for its distinct pharmacological properties and applications.
Classification:
Ferrous tartrate belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom, classified under the direct parent group Beta hydroxy acids and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Hydroxy acids and derivatives class, specifically within the Beta hydroxy acids and derivatives subclass.
Categories:
Ferrous tartrate is categorized under the following therapeutic classes: Antianemic Preparations, Blood and Blood Forming Organs, Iron Bivalent, Oral Preparations, Iron Preparations. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ferrous tartrate is a type of Hematological Agents
Hematological agents, belonging to the pharmaceutical API category, are a vital class of drugs used in the treatment of various blood disorders and hematological conditions. These agents play a crucial role in managing diseases related to the blood and its components, such as red blood cells, white blood cells, platelets, and plasma.
One significant application of hematological agents is in the treatment of anemia, a condition characterized by a low red blood cell count or hemoglobin level. Hematopoietic growth factors, a subclass of hematological agents, stimulate the production of red blood cells and enhance their maturation, thereby addressing anemia.
Another area where hematological agents demonstrate their therapeutic potential is in the treatment of blood cancers, such as leukemia, lymphoma, and multiple myeloma. These agents, including chemotherapy drugs and targeted therapies, help suppress the abnormal growth of cancer cells and restore normal blood cell production.
Hematological agents also find application in managing bleeding disorders, such as hemophilia and thrombocytopenia. They work by promoting blood clotting and preventing excessive bleeding. Additionally, certain hematological agents function as immunosuppressants, playing a crucial role in hematopoietic stem cell transplantation and preventing graft-versus-host disease.
Overall, hematological agents form a vital category within the pharmaceutical API domain, offering targeted treatments for a range of blood disorders and playing a significant role in improving the quality of life for patients with hematological conditions.
